We are a research-based healthcare company. MSD is currently a leader in a broad range of therapeutic areas, including cardiology, infectious diseases, diabetes, respiratory, vaccines and women's health, and is also focused on expanding offerings in other areas, such as neurology, oncology and dermatology.

In November 2009, MSD and Schering-Plough merged, and the combined company has a powerful late-stage research and development pipeline with greater depth and breadth, many promising drug candidates, a significantly broader portfolio of products, and presence in more than 140 countries.

Our History - MSD first established its presence in Malaysia with staff strength of 5 in 1965. In 1978, MSD licensed its business to a distributor, forming a division within the distributor’s business group. In 1993, MSD was established as an entity in Singapore which undertook the sales and marketing functions the following year.

In December 1997, the Malaysian entity was established as a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, with staff strength of about 70 and revenue of RM40 million. MSD continued to grow with local establishment of functions such medical affairs, human resources, strategic marketing and sales, and communications besides sales and marketing.

Today, MSD in Malaysia has staff strength and revenue of over 300 and RM400 million respectively. MSD is committed to establishing itself as a true leader in healthcare, a company that is the best at anticipating and meeting the needs of patients and healthcare providers.